精彩内容近段时间,集采消息频传:安徽拟启动92个品种带量联动,河北联盟集采中选结果出炉,国采1-8批接续报量结束;浙江组建的45个品种集采提上日程,不乏碘佛醇注射剂、依西美坦口服常释剂型等2024年在中国公立医疗机构终端销售额超10亿元的重磅品种,以及肺力咳合剂、脑心通胶囊等独家中成药(含剂型独家,下同)。集采持续推进“提质扩面”,中成药集采热浪四起,其战火已加速向OTC品种延伸。集采品种持续优化...
Source Link精彩内容近段时间,集采消息频传:安徽拟启动92个品种带量联动,河北联盟集采中选结果出炉,国采1-8批接续报量结束;浙江组建的45个品种集采提上日程,不乏碘佛醇注射剂、依西美坦口服常释剂型等2024年在中国公立医疗机构终端销售额超10亿元的重磅品种,以及肺力咳合剂、脑心通胶囊等独家中成药(含剂型独家,下同)。集采持续推进“提质扩面”,中成药集采热浪四起,其战火已加速向OTC品种延伸。集采品种持续优化...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.